As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast cancer awareness activations.

A weekend focused on women’s health and women’s basketball, all in Eli Lilly’s home state of Indiana? Consider that a layup ...

Eli Lilly LLY announced results from the phase III EMBER-3 study, ... Sales of this drug have been rising, driven by strong demand in the early breast cancer (EBC) indication.

Cancer conversations are evolving beyond awareness months, with increased focus on personal journeys, breakthroughs and patient experiences.

Study Overview: Eli Lilly and Company is conducting a clinical study titled ‘EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in ...

On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative ...

Eli Lilly (LLY) reported positive Phase 3 data for its drug candidate imlunestrant as both a combination and monotherapy in the treatment of advanced breast cancer. Read more here.

A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.

On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative ...

Eli Lilly's Phase 3 EMBER-3 trial shows imlunestrant improves progression-free survival in advanced ER+ breast cancer patients with ESR1 mutations.